OncLive TV

Misty D. Shields, MD, PhD, discusses the implications of the ADRIATIC trial of adjuvant therapy with durvalumab vs placebo in patients with LS-SCLC.

Corey J. Langer, MD, discusses how the use of adjuvant immunotherapy has affected the resectable NSCLC treatment paradigm.

Lori A. Leslie, MD, discusses efficacy data from the phase 2 ZUMA-5 trial evaluating axi-cel in relapsed/refractory marginal zone lymphoma.

Kanwal PS Raghav, MBBS, MD, discusses ABBV-400 in combination with fluorouracil, folinic acid, and bevacizumab in previously treated mCRC.

Efrat Dotan, MD, discusses gemcitabine plus nab-paclitaxel vs 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with metastatic pancreatic cancer.

Shyam A. Patel, MD, PhD, discusses secondary prevention strategies that may mitigate the risk of developing SPCs after receipt of CAR T-cell therapy.

Saurabh Dahiya, MD, FACP, details the pathobiology of second primary cancers following receipt of CAR T-cell therapy for hematologic malignancies.

Vikas S. Ostwal, MD, discusses data for trastuzumab emtansine (T-DM1) as second-line therapy in patients with HER2-positive advanced biliary tract cancers.

Alexander I. Spira MD, PhD, FACP, FASCO, details the next steps for amivantamab in patients with EGFR–mutated locally advanced non–small cell lung cancer.

Adam DuVall, MD, MPH, discusses remaining questions regarding the optimal use of blinatumomab in frontline B-ALL.

Marco Davila, MD, PhD, discusses emerging strategies to overcome resistance to CD19-directed CAR T-cell therapy in aggressive large B-cell lymphoma.

Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses data that have been reported with zongertinib in patients with HER2-mutated NSCLC.

Aditya Bardia, MD, MPH, FASCO, discusses the FDA approval of T-DXd for patients with pretreated HER2-low and -ultralow metastatic breast cancer.

Michael Foote, MD, discusses the use of EGFR inhibitors in the first vs subsequent lines of therapy for patients with metastatic colorectal cancer.

Marcella Ali Kaddoura, MD, discusses challenges in integrating whole genome sequencing into routine clinical practice for myeloma.

Thierry André, MD, discusses the efficacy of nivolumab plus ipilimumab vs nivolumab monotherapy in MSI-H/dMMR mCRC.

Martin Dreyling, MD, discusses ongoing trials exploring chemotherapy-free strategies in mantle cell lymphoma using BTK inhibitors.

Toni K. Choueiri, MD, discusses the significance of targeting HIF-2α using NKT2152 in previously treated advanced clear cell renal cell carcinoma.

Aditya Shreenivas, MD, MS, discusses the association between MUC1 and Claudin 18 in GI cancers.

David Samuel Dicapua Siegel, MD, discusses the current and future role for mezigdomide in the multiple myeloma treatment paradigm.

Jonathan R. Strosberg, MD, discusses the evaluation of cabozantinib vs placebo in patients with advanced gastrointestinal neuroendocrine tumors.

Daniel DeAngelo, MD, PhD, discusses data supporting the FDA approval of obe-cel for patients with relapsed or refractory B-cell precursor ALL.

Andrew Ip, MD, discusses the importance of making informed clinical decisions when selecting CAR T-cell therapy in older vs younger patients with LBCL.

Yousef Zakharia, MD, discusses the long-term benefits of nivolumab plus ipilimumab according to risk status in clear cell renal cell carcinoma.

Aasma Shaukat, MD, MPH, discusses the sensitivity of the PREEMPT CRC blood-based assay in detecting colorectal cancer for patients at average risk.

Mansi R. Shah, MD, highlights the data on the effects of IVIG on infections in patients with relapsed/refractory multiple myeloma treated with teclistamab.

Paul E. Oberstein, MD, discusses the efficacy and safety of pamrevlumab plus chemotherapy in first- and second-line PDAC.

Nazli Dizman, MD, explains the rationale for evaluating the impact of CBM588 on the gut microbiome in patients with metastatic RCC.

Hidehito Horinouchi, MD, PhD, discusses safety data for adjuvant alectinib vs chemotherapy in ALK-positive non–small cell lung cancer.

Alexander C.J. Van Akkooi, MD, PhD, FRACS, discusses how discrepancies in local and central pathologic review can expose patients to potential toxicities associated with overtreatment for metastatic melanoma.